These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9813066

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
    Fiorani P, Amatruda JF, Silvestri A, Butler RH, Bjornsti MA, Benedetti P.
    Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
    [Abstract] [Full Text] [Related]

  • 3. Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.
    Colley WC, van der Merwe M, Vance JR, Burgin AB, Bjornsti MA.
    J Biol Chem; 2004 Dec 24; 279(52):54069-78. PubMed ID: 15489506
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death.
    Megonigal MD, Fertala J, Bjornsti MA.
    J Biol Chem; 1997 May 09; 272(19):12801-8. PubMed ID: 9139740
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
    Wright CM, van der Merwe M, DeBrot AH, Bjornsti MA.
    J Biol Chem; 2015 May 08; 290(19):12068-78. PubMed ID: 25795777
    [Abstract] [Full Text] [Related]

  • 8. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
    Woo MH, Vance JR, Marcos AR, Bailly C, Bjornsti MA.
    J Biol Chem; 2002 Feb 08; 277(6):3813-22. PubMed ID: 11733535
    [Abstract] [Full Text] [Related]

  • 9. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
    Fertala J, Vance JR, Pourquier P, Pommier Y, Bjornsti MA.
    J Biol Chem; 2000 May 19; 275(20):15246-53. PubMed ID: 10809761
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons.
    Fiorani P, Reid RJ, Schepis A, Jacquiau HR, Guo H, Thimmaiah P, Benedetti P, Bjornsti MA.
    J Biol Chem; 2004 May 14; 279(20):21271-81. PubMed ID: 14990574
    [Abstract] [Full Text] [Related]

  • 14. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.
    Jacquiau HR, van Waardenburg RC, Reid RJ, Woo MH, Guo H, Johnson ES, Bjornsti MA.
    J Biol Chem; 2005 Jun 24; 280(25):23566-75. PubMed ID: 15817450
    [Abstract] [Full Text] [Related]

  • 15. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
    Sirikantaramas S, Meeprasert A, Rungrotmongkol T, Fuji H, Hoshino T, Sudo H, Yamazaki M, Saito K.
    Phytochemistry; 2015 May 24; 113():50-6. PubMed ID: 25733498
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants.
    Knab AM, Fertala J, Bjornsti MA.
    J Biol Chem; 1993 Oct 25; 268(30):22322-30. PubMed ID: 8226741
    [Abstract] [Full Text] [Related]

  • 17. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.
    Woo MH, Losasso C, Guo H, Pattarello L, Benedetti P, Bjornsti MA.
    Proc Natl Acad Sci U S A; 2003 Nov 25; 100(24):13767-72. PubMed ID: 14585933
    [Abstract] [Full Text] [Related]

  • 18. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
    Benedetti P, Fiorani P, Capuani L, Wang JC.
    Cancer Res; 1993 Sep 15; 53(18):4343-8. PubMed ID: 8395982
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, Pommier Y.
    Cancer Res; 2001 Mar 01; 61(5):1964-9. PubMed ID: 11280753
    [Abstract] [Full Text] [Related]

  • 20. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
    D'Annessa I, Tesauro C, Wang Z, Arnò B, Zuccaro L, Fiorani P, Desideri A.
    Biochim Biophys Acta; 2013 Dec 01; 1834(12):2712-21. PubMed ID: 24096022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.